Brendan P. Eckelman, Chief Scientific Officer, 10% Owner at Inhibrx, Inc. (INBX), sold 80,000 shares at $33.90 ($2.7M) on 2022-11-01, disclosed to the SEC on 2022-11-02.
Open-market sale of $2.7M INBX by Chief Scientific Officer, 10% Owner. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $33.34 | 27,651 | $922K | 34.4% |
| 2 | $33.34 | 27,651 | $922K | 34.4% |
| 3 | $33.90 | 12,349 | $419K | 15.6% |
| 4 | $33.90 | 12,349 | $419K | 15.6% |
| Total | $33.51 avg | 80,000 | $2.7M | 100% |
| Filing → |
| INBX | SELL | 2022-12-07 | $2.1M | — | Filing → |
| INBX | SELL | 2022-10-05 | $2.2M | — | Filing → |
| INBX | SELL | 2022-09-07 | $1.2M | — | Filing → |